SAN FRANCISCO – Merriman Capital, Inc. (“Merriman”), a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that it has been retained as capital markets advisor to Pressure BioSciences, Inc. (“the Company”) (OTCQB: PBIO). In this capacity, Merriman will advise Pressure BioSciences’ management on various strategic initiatives focused on increasing shareholder value. These initiatives include the effective engagement of a potentially broader institutional shareholder base, strategies intended to increase trading liquidity, evaluation of various strategic capital markets initiatives, and opportunities to pursue other venues, such as NYSE, NASDAQ, AMEX, and the OTCQX.

Pressure BioSciences is focused on laboratory biological sample preparation through the harnessing of hydrostatic pressure. The Company has developed and patented a process called pressure cycling technology, or PCT, which applies cycles of hydrostatic pressure to effectively control the action of molecules in biological cell and tissue samples. PCT sample preparation systems and its enhancements are used in forensics, bio-therapeutics, vaccine development, soil and plant technology and counter-bioterror applications.

“Pressure BioSciences is a very welcome addition to our expanding universe of corporate advisory clients,” said Douglas Rogers, Managing Director and Head of the Capital Markets Advisory Group. “Providing our clients with market insight, corporate brokerage services and strategic advisory relating to their capital structure, as well as market engagement practices and overall public markets strategy initiatives are central to Merriman’s advisory platform. We look forward to supporting the Pressure BioSciences management team in our capacity as their capital markets advisor, as we work with them to help grow shareholder value in PBI.”

About Merriman Capital, Inc.

Merriman Capital, Inc. is a corporate advisory-focused registered investment bank that provides equity and options execution services, market making, and differentiated research for high growth companies. The firm also provides capital formation, advisory, and M&A services. Merriman Capital, Inc. is a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR) and is the leading investment banking firm for unique high-growth companies. For more information, please go to https://www.merrimanco.com.

Merriman Capital, Inc. is a registered broker-dealer and member of The Financial Industry Regulatory Authority (FINRA) https://www.finra.org/ and the Securities Investor Protection Corporation (SIPC) https://www.sipc.org/.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (“PCT”). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.